Segall Bryant & Hamill’s Cocrystal Pharma COCP Stock Holding History

Segall Bryant & Hamill’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,083	Closed	-$9K	–	783
2020 Q1	$9K	Sell	1,083 -125	-10%	-$1.18K	﹤0.01%	780
2019 Q4	$7K	Sell	1,208 -134	-10%	-$1.34K	﹤0.01%	816
2019 Q3	$33K	Sell	1,342 -74	-5%	-$1.92K	﹤0.01%	814
2019 Q2	$40K	Buy	1,416 +60	+4%	+$1.78K	﹤0.01%	805
2019 Q1	$44K	Buy	1,356 +354	+35%	+$13K	﹤0.01%	813
2018 Q4	$43K	Buy	1,002 +44	+5%	+$1.45K	﹤0.01%	810
2018 Q3	$29K	Sell	958 -84	-8%	-$3.76K	﹤0.01%	839
2018 Q2	$46K	Buy	+1,042	New	+$38.7K	﹤0.01%	849

Other funds holding COCP

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Emory University Atlanta, Georgia $267M AUM 48.26% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Segall Bryant & Hamill's COCP Position: Q2 2020 in Review

Segall Bryant & Hamill sold out of Cocrystal Pharma (COCP) in Q2 2020, closing a stake of 1,083 shares — an estimated $9K sold.

Segall Bryant & Hamill first reported a position in COCP in Q2 2018 and held it in 8 quarters. The position peaked at $46K in Q2 2018. 21 funds tracked by Wall St. Rank hold COCP as of Q2 2020.

Segall Bryant & Hamill reported no remaining Cocrystal Pharma position as of Q2 2020 after selling out during the quarter.
Segall Bryant & Hamill sold 1,083 Cocrystal Pharma shares in Q2 2020, an estimated $9K.
Segall Bryant & Hamill first reported a position in Cocrystal Pharma in Q2 2018 and held it in 8 quarters.
Segall Bryant & Hamill's Cocrystal Pharma position peaked at $46K in Q2 2018.
21 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2020.

Based on Segall Bryant & Hamill's 13F filing for Q2 2020, filed 14 Aug 2020.